EX-99.1 2 tm2610558d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with idiopathic pulmonary fibrosis, with positive results observed across all subgroups Integrated analyses of TETON-1 and TETON-2 showed statistically significant treatment effects across the primary and most secondary efficacy endpoints, reinforcing the robustness of the clinically meaningful results observed in each of the individual studies Nebulized Tyvaso combines direct lung delivery with multimodal activity across fibrotic, vascular, and inflammatory pathways that are not currently addressed by existing IPF therapies United Therapeutics plans to seek priority review of a supplemental New Drug Application to be submitted to the FDA by the end of this summer SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
United Therapeutics Corporation
UTHRNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events On March 30, 2026, United Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibits 99.1 and is incorporated herein by reference. TYVASO is a registered trademark of United Therapeutics Corporation.
Company context
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.